Tech Company Financing Transactions
Avenue Biosciences Funding Round
On 1/12/2026, Avenue Biosciences raised $5.7 million in Seed financing from Tesi, Inventure and University of Helsinki.
Transaction Overview
Company Name
Announced On
1/12/2026
Transaction Type
Venture Equity
Amount
$5,700,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to scale the first technology for measuring and modulating the efficacy of the protein secretory pathway, a critical bottleneck affecting the development and manufacturing of therapeutic proteins.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Viikinkaari 1A
Helsinki, 00790
Finland
Helsinki, 00790
Finland
Phone
Undisclosed
Website
Email Address
Overview
Proteins are foundational to therapeutic discovery and human health. The use of machine learning and artificial intelligence is set to revolutionize the development of protein biologics and tools for biotechnology processes. A unique high throughput chemistry combined with our software platform are now opening a new dimension for the industry.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tero-Pekka Alastalo
Chief Operating Officer
Katja Rosti
Chief Scientific Officer
Juho Kellosalo
Chief Scientific Officer
Anton Klåvus
VP - Marketing
Juulia Simonen
Browse more venture capital transactions:
Prev: 1/12/2026: Torq venture capital transaction
Next: 1/12/2026: Orca Bio venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs